Start with the tell: in 2024, the prime-editing patents weren't mostly about whether the technique works. They were about making it work well. That shift — from concept to efficiency — is how you spot a maturing technology in the filing record.

Prime editing rewrites DNA letters directly instead of cutting both strands, which makes it precise but, historically, slow and low-yield. A field still proving the concept files broad mechanism claims. A field tuning a working tool files narrow improvement claims. By 2024, the balance had tipped to the latter.

“Provided herein are compositions and methods for inducing CRISPR/Cas-based editing of a target nucleic acid (e.g., target DNA or target RNA) in vitro or in a cell, using modified prime editing guide RNAs (pegRNAs) that incorporate one or more chemically-modified nucleotides.”— U.S. Patent No. 11,884,915 source

Agilent's grant US11884915B2 on chemically modified guide RNAs for prime editing is exactly an efficiency claim — small molecular tweaks that make the edit take more reliably. Its companion US20240218354A1 covers the same modified-guide approach.

Other 2024 filings push reliability and yield. Publication US20240409907A1 covers improving prime-editing efficiency with cis-acting regulatory elements — bolting on sequence helpers that raise the editing rate. Multiple independent groups optimizing the same step is the trend signal.

The caveat stays the same: a count of efficiency patents tells you the technology is being refined, not that any prime-editing therapy has reached patients. Refinement is necessary but not sufficient.

By the numbers, though, 2024 reads as prime editing's coming-of-age in the patent record. The conversation in the filings moved from 'this is possible' to 'here's how to make it good enough' — and that's the conversation that precedes real-world use.